Don't Miss Out

Subscribe to OCA's News & Alerts.

Do You Know Why There Isn't an EUA for Fluvoxamine?

The drug works. Amazingly well. Better than anything else against COVID when given early. So why isn't there an EUA? The answer will surprise you. Or maybe not.

Abstract

Doctors today are driven by what the NIH says, not science. The NIH ignores everything that isn't big pharma.


Example: The Pfizer 6-month trial showed no all-cause mortality benefit; in fact, if anything, it showed that the vaccine killed more people than it saved. Sure, one COVID life was saved per 22,000 fully vaxed, but the all-cause mortality strongly favored the placebo (21 died in vaccine group vs. 17 in placebo). Doctors rush to recommend it. Nobody is skeptical.

Fluvoxamine on the other hand actually demonstrated a 12 times reduction in all-cause mortality in the Phase 3 trial. It really saved lives and the difference was dramatic in the clinical trial: “There was one death in the fluvoxamine group and 12 in the placebo group for the per-protocol population (OR 0·09; 95% CI 0·01–0·47).” But the NIH ignored the drug and didn’t even mention this astonishing result on the NIH treatment guidelines. The study wasn’t even mentioned at all in the guidelines. It was like it never happened. So doctors play along an ignore the drug too. No complaints from anyone in the medical community. Silence.